Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

MEPs Slate EU Industry Practices In Report On Barriers To Medicines Access

Executive Summary

The European Parliament’s environment and public health committee has produced a set of recommendations for a new approach to tackling barriers to medicines in the EU. There’s a particular focus on pricing strategies, intellectual property, and delays to generic competition.


Related Content

MEPs And Health Advocates Pile The Pressure On EU Drug Pricing
UN Panel Report: Positions Still Polarized Over Medicines Access Barriers
EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body
NGOs Urge EU Ministers To Resist 'Industry Pressure' and Reform RnD Model, Raise Regulatory Standards